Study to Determine Effectiveness of Dietary Monosaccharide Supplementation in Patients with Congenital Disorders of Glycosylation


About this study

The purpose of this study is to assess the safety and tolerability of oral monosaccharide (galactose and fucose) treatment in a small pilot group of congenital disorders of glycosylation patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  •  Patient is younger than 21 years old.
  • Patient has a biochemically and genetically proven congenital disorder of glycosylation.

Exclusion Criteria:

  • Patient has Aldolase B deficiency.
  • Patient has Galactosemia.
  • Patient has Hemolytic uremic syndrome.
  • Patient has severe anemia.
  • Patient has galactose intolerance.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Eva Morava-Kozicz, M.D., Ph.D.

Open for enrollment

Contact information:

Sarah Bohlen B.S.

(507) 293-7485

More information


Publications are currently not available

Mayo Clinic Footer